Dr. Dreyling on Results for Copanlisib in Patients With B-Cell Lymphoma

Video

Martin Dreyling, MD, associate professor, University of Munich, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma, during the AACR Annual Meeting.

Martin Dreyling, MD, professor of medicine, University of Munich Hospital in Grosshadern, discusses primary results of the pivotal CHRONOS-1 study, which looked at copanlisib in patients with relapsed or refractory indolent B-cell lymphoma, during the AACR Annual Meeting.

Although there are treatments options currently available for these patients, all of the 142 patients included in the study had already undergone at least 2 prior lines of therapy, with the majority of the patients being refractory to the previous approaches.

Surprisingly, these patients still responded to the PI3K inhibitor copanlisib, Dreyling says. In fact, there was almost a 60% response rate demonstrated in the study. In marginal zone lymphoma, the response rate was almost 70%, and the duration of the response was 22 months, Dreyling explains.

With regard to toxicity, Dreyling adds there was no major colitis observed, and elevated liver enzymes have rarely been observed.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Guenther Koehne, MD, PhD
Lori A. Leslie, MD, an expert on lymphoma
Lori A. Leslie, MD, an expert on lymphoma
A panel of 4 experts on MDS
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania